MK-6024

· Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-6024, covering 2025-07-15 to 2025-07-15. Get the full timeline:

Most recent: Clinical Trial Update: Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016) [Phase 2]

See pricing